Scinai Immunotherapeutics (SCNI) Competitors $2.33 -0.05 (-2.10%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. AYTU, ORGS, BCLI, ADXN, CTXR, SNSE, BTAI, SLXN, ACXP, and TSBXShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Aytu BioPharma (AYTU), Orgenesis (ORGS), Brainstorm Cell Therapeutics (BCLI), Addex Therapeutics (ADXN), Citius Pharmaceuticals (CTXR), Sensei Biotherapeutics (SNSE), BioXcel Therapeutics (BTAI), Silexion Therapeutics (SLXN), Acurx Pharmaceuticals (ACXP), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Aytu BioPharma Orgenesis Brainstorm Cell Therapeutics Addex Therapeutics Citius Pharmaceuticals Sensei Biotherapeutics BioXcel Therapeutics Silexion Therapeutics Acurx Pharmaceuticals Turnstone Biologics Scinai Immunotherapeutics (NASDAQ:SCNI) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk. Does the MarketBeat Community believe in SCNI or AYTU? Aytu BioPharma received 255 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformScinai ImmunotherapeuticsN/AN/AAytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Which has more risk and volatility, SCNI or AYTU? Scinai Immunotherapeutics has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Does the media refer more to SCNI or AYTU? In the previous week, Aytu BioPharma had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 5 mentions for Aytu BioPharma and 3 mentions for Scinai Immunotherapeutics. Aytu BioPharma's average media sentiment score of 0.40 beat Scinai Immunotherapeutics' score of 0.29 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, SCNI or AYTU? Scinai Immunotherapeutics has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScinai Immunotherapeutics$658K3.54-$6.50M-$9.57-0.24Aytu BioPharma$81.66M0.15-$15.84M-$0.72-2.71 Do insiders & institutionals hold more shares of SCNI or AYTU? 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 3.6% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is SCNI or AYTU more profitable? Scinai Immunotherapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -7.62%. Scinai Immunotherapeutics' return on equity of 0.00% beat Aytu BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Scinai ImmunotherapeuticsN/A N/A -30.48% Aytu BioPharma -7.62%-19.30%-4.80% SummaryScinai Immunotherapeutics beats Aytu BioPharma on 8 of the 14 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.33M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.0132.9027.1419.96Price / Sales3.54466.20411.83157.63Price / CashN/A168.6838.2534.64Price / Book-0.243.427.064.69Net Income-$6.50M-$72.35M$3.23B$248.14M7 Day Performance-28.31%7.27%2.67%2.39%1 Month Performance-8.27%17.53%8.82%6.05%1 Year Performance-13.38%-17.27%31.44%13.60% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics0.6563 of 5 stars$2.33-2.1%N/A-13.8%$2.33M$658K-0.0120News CoverageShort Interest ↑AYTUAytu BioPharma1.4903 of 5 stars$1.55-12.9%N/A-36.4%$9.56M$81.66M-1.07160Short Interest ↓Gap UpORGSOrgenesis1.56 of 5 stars$1.95+0.1%N/AN/A$9.35M$662K0.00150Gap UpBCLIBrainstorm Cell Therapeutics4.0016 of 5 stars$1.08-2.7%$30.00+2,677.8%-81.1%$8.57MN/A-0.2340Short Interest ↑ADXNAddex Therapeutics2.5243 of 5 stars$8.08-0.1%$30.00+271.3%-1.2%$8.57M$404.10K-23.7630Positive NewsGap UpCTXRCitius Pharmaceuticals2.4306 of 5 stars$0.87+13.0%$54.50+6,164.4%-93.7%$8.55MN/A0.0020News CoverageAnalyst ForecastGap DownHigh Trading VolumeSNSESensei Biotherapeutics4.744 of 5 stars$0.34+7.3%$4.50+1,231.0%-53.9%$8.52MN/A-0.2840Positive NewsShort Interest ↓BTAIBioXcel Therapeutics3.9021 of 5 stars$1.37+3.8%$42.60+3,009.5%-92.2%$8.30M$1.85M-0.0490Short Interest ↑SLXNSilexion TherapeuticsN/A$0.95-1.0%$5.00+426.0%N/A$8.26MN/A0.00N/AUpcoming EarningsGap DownACXPAcurx Pharmaceuticals3.2513 of 5 stars$0.35-7.7%$8.00+2,198.9%-86.3%$8.17MN/A-0.323Positive NewsHigh Trading VolumeTSBXTurnstone Biologics3.3047 of 5 stars$0.35+11.9%$0.45+28.6%-87.5%$8.10M$19.31M-0.1182Positive NewsShort Interest ↓Gap UpHigh Trading Volume Related Companies and Tools Related Companies Aytu BioPharma Alternatives Orgenesis Alternatives Brainstorm Cell Therapeutics Alternatives Addex Therapeutics Alternatives Citius Pharmaceuticals Alternatives Sensei Biotherapeutics Alternatives BioXcel Therapeutics Alternatives Silexion Therapeutics Alternatives Acurx Pharmaceuticals Alternatives Turnstone Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCNI Stock Free SCNI Stock Alerts